

Ontario Public Drug Programs

Drug Submission Status

Generic Name: triptorelin pamoate

Brand Name: Trelstar

Strength: 22.5mg powder for suspension, sustained-release

Manufacturer: Paladin Labs Inc.

Indication: The palliative treatment of hormone dependent advanced carcinoma of the prostate gland

Rapid Review: Not requested

| Submission Type: | Date Submission Received: | Date Submission Deemed Complete: | Review Status: | Funding Decision: |
|--------------------------------------|---------------------------|----------------------------------|----------------------|---|
| First Review (Initial Submission) | 18/12/2013 | 03/03/2014 | EO decision rendered | Listed on the Ontario Drug Benefit Formulary as a General Benefit |

Rapid Review:

Details of the Rapid Review process can be found at:

www.health.gov.on.ca/en/pro/programs/drugs/drug_submissions/rapid_review_process.aspx

Review Status:

- Screening – Ministry is screening the manufacturer’s submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete – Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review – Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.

- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed – A recommendation was made by the CED.
- Executive Officer (EO) decision rendered.

Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at:

www.health.gov.on.ca/en/pro/programs/drugs/ced_rec_table.aspx

Updated: October 24, 2014